Moderna Inc [NASDAQ: MRNA] gained 5.10% or 3.72 points to close at $76.61 with a heavy trading volume of 5313652 shares.
The daily chart for MRNA points out that the company has recorded -25.64% loss over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 3.78M shares, MRNA reached to a volume of 5313652 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Moderna Inc [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $124.11 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.42. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
HSBC Securities have made an estimate for Moderna Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on August 28, 2024. While these analysts kept the previous recommendation, Deutsche Bank dropped their target price from $85 to $80. The new note on the price target was released on August 07, 2024, representing the official price target for Moderna Inc stock. Previously, the target price had yet another drop from $125 to $90, while RBC Capital Mkts kept a Sector Perform rating on MRNA stock. On February 26, 2024, analysts increased their price target for MRNA shares from 75 to 86.
The Average True Range (ATR) for Moderna Inc is set at 4.05, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 5.84. The Price to Book ratio for the last quarter was 2.51, with the Price to Cash per share for the same quarter was set at 22.08.
Trading performance analysis for MRNA stock
Moderna Inc [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.02. With this latest performance, MRNA shares dropped by -9.14% in over the last four-week period, additionally sinking by -25.64% over the last 6 months – not to mention a drop of -29.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 34.65, with the RSI for the last a single of trading hit 39.49, and the three-weeks RSI is set at 33.75 for Moderna Inc [MRNA]. The present Moving Average for the last 50 days of trading for this stock 99.30, while it was recorded at 73.67 for the last single week of trading, and 106.23 for the last 200 days.
Moderna Inc [MRNA]: A deeper dive into fundamental analysis
Moderna Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.92 and a Current Ratio set at 4.09.
An analysis of Institutional ownership at Moderna Inc [MRNA]
There are presently around $72.72%, or 80.37%% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 43.45 million shares, which is approximately 11.3741%. VANGUARD GROUP INC, holding 39.56 million shares of the stock with an approximate value of $$4.7 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $$3.04 billion in MRNA stock with ownership which is approximately 6.6917%.
